Search
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigational[L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363]
Icosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceuticalImportant polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. … A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane
Mixtures: TODAVİT IM/IV ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 4 ADET, Omega-3 Iq Childrens ChewableMemantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalInitially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million.
Categories: N-methyl-D-aspartate Receptor AntagonistProducts: ZAHARME IRAzilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalenzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. … [A7354] Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersAluminum chloride
go.drugbank.com/drugs/DB11081ApprovedInvestigationalIn antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15%, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form [L2012]. … It may also be found in over-the-counter as an antiperspirant or prescription products as an antihemorrhagic agent.
Mixtures: Sulpak II, Anti-perspirant Roll-ON DeodCategories: Compounds used in a research, industrial, or household settingSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigational[L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR … [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology.
Inositol
go.drugbank.com/drugs/DB13178ApprovedInvestigationalWithdrawnIt is considered a pseudovitamin as it is a molecule that does not qualify to be an essential vitamin because even though its presence is vital in the body, a deficiency in this molecule does not translate … These molecules have structural similarities to glucose and are involved in cellular signaling.
Mixtures: Multi II IV Vi Tab, Card-floe II TabLonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380,L10971] Lonapegsomatropin was granted FDA approval on 25 August 2021.[L36380] It was later approved by the European Commission on 13 January 2022.[L39900] … Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and older, weighing at least
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Mixtures: Primaxin Im, Primaxin IVSynonyms: N-formimidoylthienamycin, N-formimidoyl thienamycin